These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 19118572

  • 1. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
    Gil JM, Rego AC.
    Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
    [Abstract] [Full Text] [Related]

  • 2. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.
    Bailey CD, Johnson GV.
    J Neurochem; 2005 Jan; 92(1):83-92. PubMed ID: 15606898
    [Abstract] [Full Text] [Related]

  • 3. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
    Zourlidou A, Gidalevitz T, Kristiansen M, Landles C, Woodman B, Wells DJ, Latchman DS, de Belleroche J, Tabrizi SJ, Morimoto RI, Bates GP.
    Hum Mol Genet; 2007 May 01; 16(9):1078-90. PubMed ID: 17360721
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.
    Crocker SF, Costain WJ, Robertson HA.
    Brain Res; 2006 May 09; 1088(1):176-86. PubMed ID: 16626669
    [Abstract] [Full Text] [Related]

  • 7. Global changes to the ubiquitin system in Huntington's disease.
    Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H, Kopito RR.
    Nature; 2007 Aug 09; 448(7154):704-8. PubMed ID: 17687326
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease.
    Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden M, Borchelt D, Ross CA, Ferrante RJ, Beal MF.
    J Neurochem; 2005 Oct 09; 95(2):553-62. PubMed ID: 16135087
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
    Conforti P, Ramos C, Apostol BL, Simmons DA, Nguyen HP, Riess O, Thompson LM, Zuccato C, Cattaneo E.
    Mol Cell Neurosci; 2008 Sep 09; 39(1):1-7. PubMed ID: 18571429
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease.
    Josefsen K, Nielsen MD, Jørgensen KH, Bock T, Nørremølle A, Sørensen SA, Naver B, Hasholt L.
    J Neuroendocrinol; 2008 Feb 09; 20(2):165-72. PubMed ID: 18034868
    [Abstract] [Full Text] [Related]

  • 15. Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice.
    Gil JM, Leist M, Popovic N, Brundin P, Petersén A.
    BMC Neurosci; 2004 May 10; 5():17. PubMed ID: 15134587
    [Abstract] [Full Text] [Related]

  • 16. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.
    Petersén A, Chase K, Puschban Z, DiFiglia M, Brundin P, Aronin N.
    Exp Neurol; 2002 May 10; 175(1):297-300. PubMed ID: 12009780
    [Abstract] [Full Text] [Related]

  • 17. Recent advances on the pathogenesis of Huntington's disease.
    Petersén A, Mani K, Brundin P.
    Exp Neurol; 1999 May 10; 157(1):1-18. PubMed ID: 10222105
    [Abstract] [Full Text] [Related]

  • 18. IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.
    Duarte AI, Petit GH, Ranganathan S, Li JY, Oliveira CR, Brundin P, Björkqvist M, Rego AC.
    Exp Neurol; 2011 Oct 10; 231(2):314-9. PubMed ID: 21763311
    [Abstract] [Full Text] [Related]

  • 19. Animal models of Huntington's disease.
    Gárdián G.
    Ideggyogy Sz; 2006 Nov 20; 59(11-12):396-9. PubMed ID: 17203874
    [Abstract] [Full Text] [Related]

  • 20. Recent insights into the molecular pathogenesis of Huntington disease.
    Leavitt BR, Wellington CL, Hayden MR.
    Semin Neurol; 1999 Nov 20; 19(4):385-95. PubMed ID: 10716661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.